Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model

Biologics: Targets and Therapy

Volumn 3, Issue , 2009, Pages 27-37

  Scholz, Markuz ^a   Ackermann, Manuela ^a   Emmrich, Frank ^a   Loeffler, Markus ^a   Kamprad, Manja ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Chemotherapy toxicity; Cyclophosphamide; Cytopenia; Mice; Neutropenia; rhG CSF

Indexed keywords

CYCLOPHOSPHAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; CYTOPENIA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; GRANULOCYTOPENIA; LYMPHOCYTOPENIA; MONOCYTOPENIA; MOUSE; NONHUMAN; OPTIMAL DRUG DOSE; SINGLE DRUG DOSE;

EID: 65349098791     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Article

References (80)

1. Epelbaum R, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variables. Cancer. 1990;66:1124-1129.
2. Gregory SA, Trumper L. Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes? Ann Oncol. 2005;16:1413-1424.
3. Hortobagyi GN. Progress in systemic chemotherapy of primary breast cancer: an overview. J Natl Cancer Inst Monogr. 2001:72-79.
4. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8:963-977.
5. Marangolo M, Bengala C, Conte PF, et al. Dose and outcome: the hurdle of neutropenia. Oncol Rep. 2006;16:233-248.
6. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol. 1993;4:651-656.
7. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998; 90:1205-1211.
8. von Minckwitz G, Raab G, Caputo A, et al. Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol. 2005;23:2676-2685.
9. Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol. 2003;21:2466-2473.
10. Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626-633.
11. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. Highdose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol. 1995;13:2916-2923.
12. Diehl V, Franklin J, Pfreundschuh M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med. 2003;348:2386-2395.
13. Sternberg CN, de Mulder PH, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J Clin Oncol. 2001;19:2638-2646.
14. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol. 2000;18:395-404.
15. Blayney DW, McGuire BW, Cruickshank SE, Johnson DH. Increasing chemotherapy dose density and intensity: phase I trials in non-small cell lung cancer and non-Hodgkin's lymphoma. Oncologist. 2005;10:138-149.
16. Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2003;14:881-893.
17. Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in six European audits of breast cancer treatment. Support Care Cancer. 2006;14:901-909.
18. Siena S, Secondino S, Giannetta L, Carminati O, Pedrazzoli P. Optimising management of neutropenia and anaemia in cancer chemotherapy-advances in cytokine therapy. Crit Rev Oncol Hematol. 2003;48:S39-S47.
19. Kuderer NM, Dale DC, Crawford J, Cosler LE, Lyman GH. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006;106:2258-2266.
20. Dale D. Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factors. Semin Oncol. 2003;30:3-9.
21. Jacobson MA, Liu RC, Davies D, Cohen PT. Human immunodeficiency virus disease-related neutropenia and the risk of hospitalization for bacterial infection. Arch Intern Med. 1997;157:1825-1831.
22. Rodriguez-Adrian LJ, Grazziutti ML, Rex JH, Anaissie EJ. The potential role of cytokine therapy for fungal infections in patients with cancer: is recovery from neutropenia all that is needed? Clin Infect Dis. 1998;26:1270-1278.
23. Mitchell PL, Morland B, Stevens MC, et al. Granulocyte colonystimulating factor in established febrile neutropenia: a randomized study of pediatric patients. J Clin Oncol. 1997;15:1163-1170.
24. Garcia-Carbonero R, Mayordomo JI, Tornamira MV, et al. Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst. 2001;93:31-38.
25. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colonystimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992;80:1430-1436.
26. Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004;100:228-237.
27. Begley CG, Nicola NA, Metcalf D. Proliferation of normal human promyelocytes and myelocytes after a single pulse stimulation by purified GM-CSF or G-CSF. Blood. 1988;71:640-645.
28. Lord BI, Bronchud MH, Owens S, et al. The kinetics of human granulopoiesis following treatment with granulocyte colony-stimulating factor in vivo. Proc Natl Acad Sci U S A. 1989;86:9499-9503.
29. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science. 1986;232:61-65.
30. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood. 1992;80:2012-2020.
31. Mackey MC, Aprikyan AA, Dale DC. The rate of apoptosis in post mitotic neutrophil precursors of normal and neutropenic humans. Cell Prolif. 2003;36:27-34.
32. Bronchud MH, Potter MR, Morgenstern G, et al. In vitro and in vivo analysis of the effects of recombinant human granulocyte colonystimulating factor in patients. Br J Cancer. 1988;58:64-69.
33. Tanaka H, Tokiwa T. Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Res. 1990;50:6615-6619.
34. Borleffs JC, Bosschaert M, Vrehen HM, et al. Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects. Clin Ther. 1998;20:722-736.
35. Ericson SG, Gao H, Gericke GH, Lewis LD. The role of polymorphonuclear neutrophils (PMNs) in clearance of granulocyte colony-stimulating factor (G-CSF) in vivo and in vitro. Exp Hematol. 1997; 25:1313-1325.
36. Khwaja A, Carver J, Jones HM, Paterson D, Linch DC. Expression and dynamic modulation of the human granulocyte colony-stimulating factor receptor in immature and differentiated myeloid cells. Br J Haematol. 1993;85:254-259.
37. Kotto-Kome AC, Fox SE, Lu W, Yang BB, Christensen RD, Calhoun DA. Evidence that the granulocyte colony-stimulating factor (G-CSF) receptor plays a role in the pharmacokinetics of G-CSF and PegG-CSF using a G-CSF-R KO model. Pharmacol Res. 2004;50:55-58.
38. El Ouriaghli F, Fujiwara H, Melenhorst JJ, Sconocchia G, Hensel N, Barrett AJ. Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis. Blood. 2003;101:1752-1758.
39. Shimazaki C, Uchiyama H, Fujita N, et al. Serum levels of endogenous and exogenous granulocyte colony-stimulating factor after autologous blood stem cell transplantation. Exp Hematol. 1995;23:1497-1502.
40. Crawford J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev. 2002;28(Suppl A):7-11.
41. Tanaka H, Satake-Ishikawa R, Ishikawa M, Matsuki S, Asano K. Pharmacokinetics of recombinant human granulocyte colonystimulating factor conjugated to polyethylene glycol in rats. Cancer Res. 1991;51:3710-3714.
42. Yang BB, Lum PK, Hayashi MM, Roskos LK. Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats. J Pharm Sci. 2004;93:1367-1373.
43. Gabrilove JL. An analysis of current neutropenia therapies, including pegfilgrastim. Clin Cornerstone. 2006;8(Suppl 5):S19-S28.
44. Lord BI, Woolford LB, Molineux G. Kinetics of neutrophil production in normal and neutropenic animals during the response to filgrastim (r-metHu G-CSF) or filgrastim SD/01 (PEG-r-metHu G-CSF). Clin Cancer Res. 2001;7:2085-2090.
45. Grigg A, Solal-Celigny P, Hoskin P, et al. Open-label, randomized study of pegfilgrastim vs. daily filgrastim as an adjunct to chemotherapy in elderly patients with non-Hodgkin's lymphoma. Leuk Lymphoma. 2003;44:1503-1508.
46. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. Ann Oncol. 2002;13:903-909.
47. Schippinger W, Holub R, Dandachi N, Bauernhofer T, Samonigg H. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim. Oncology. 2006;70:290-293.
48. Pinto L, Liu Z, Doan Q, Bernal M, Dubois R, Lyman G. Comparison of pegfi lgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2007;23:2283-2295.
49. Engel C, Scholz M, Loeffler M. A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood. 2004;104:2323-2331.
50. Scholz M, Engel C, Loeffler M. Modelling Human Granulopoiesis under Poly-chemotherapy with G-CSF Support. J Math Biol. 2005; 50:397-439.
51. Lohrmann HP, Schreml W. Cytotoxic drugs and the granulopoietic system. New York: Springer-Verlag; 1982.
52. Barrios L, Poletti OH, Agustini MI. The influence of recombinant human granulocyte colony-stimulating factor on granulopoiesis in mice recovering from cyclophosphamide treatment. Methods Find Exp Clin Pharmacol. 2000;22:275-280.
53. Barrios L, Poletti OH. Effects of filgrastim on granulopoietic cells of mice pretreated with methotrexate. Biocell. 2005;29:7-14.
54. Coleman D, Fairchild D, Schindler-Horvat J, Munyakazi L, Neumann TA. Systemic effects of pegylated recombinant human megakaryocyte growth and development factor in combination with recombinant murine granulocyte colony-stimulating factor in a murine model of myelosuppression. Toxicol Sci. 1998;45:77-87.
55. Molineux G, Kinstler O, Briddell B, et al. A new form of Filgrastim with sustained duration in vivo and enhanced ability to mobilize PBPC in both mice and humans. Exp Hematol. 1999;27:1724-1734.
56. Pospisil M, Hofer M, Netikova J, et al. Pretreatment with granulocyte colony-stimulating factor reduces myelopoiesis in irradiated mice. Radiat Res. 1999;151:363-367.
57. Bauhofer A, Celik I, Plaul U, Wulf H, Torossian A. Effects of G-CSF and antibiotic prophylaxis in a 2 × 2 factorial design on outcome in septic rats. Inflamm Res. 2004;53(Suppl 2):S126-129.
58. Misaki M, Ueyama Y, Tsukamoto G, Matsumura T. Timing of recombinant human granulocyte colony-stimulating factor administration on neutropenia induced by cyclophosphamide in normal mice. Br J Cancer. 1998;77:884-889.
59. Yankelevich M, Goodell MA, Kaplan J. Efficacy of delayed administration of post-chemotherapy granulocyte colony-stimulating factor: evidence from murine studies of bone marrow cell kinetics. Exp Hematol. 2008;36:9-16.
60. Grigg AP, Roberts AW, Raunow H, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood. 1995;86:4437-4445.
61. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med. 1966;64:328-340.
62. Ihaka R, Gentleman RR. a language for data analysis and graphics. J Comp Graph Stat. 1996;5:299-314.
63. Petursson SR, Chervenick PA. Megakaryocytopoiesis and granulopoiesis following cyclophosphamide. J Lab Clin Med.1982;100:682-694.
64. Yeager AM, Levin FC, Levin J. Effects of cyclophosphamide on murine bone marrow and splenic megakaryocyte-CFC, granulocytemacrophage-CFC, and peripheral blood cell levels. J Cell Physiol. 1982;112:222-228.
65. Chatta GS, Price TH, Allen RC, Dale DC. Effects of in vivo recombinant methionyl human granulocyte colony-stimulating factor on the neutrophil response and peripheral blood colony-forming cells in healthy young and elderly adult volunteers. Blood. 1994;84:2923-2929.
66. Johnston E, Crawford J, Blackwell S, et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol.2000;18:2522-2528.
67. Ribeiro D, Veldwijk MR, Benner A, et al. Differences in functional activity and antigen expression of granulocytes primed in vivo with filgrastim, lenograstim, or pegfilgrastim. Transfusion. 2007;47:969-980.
68. Tanaka H, Okada Y, Kawagishi M, Tokiwa T. Pharmacokinetics and pharmacodynamics of recombinant human granulocyte-colony stimulating factor after intravenous and subcutaneous administration in the rat. J Pharmacol Exp Ther. 1989;251:1199-1203.
69. Mukae H, Zamfir D, English D, Hogg JC, van Eeden SF. Polymorphonuclear leukocytes released from the bone marrow by granulocyte colony-stimulating factor: intravascular behavior. Hematol J. 2000;1:159-171.
70. Scholz M, Engel C, Loeffler M. Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia. Br J Haematol. 2006;132:723-735.
71. Hematopoietic growth factors: ESMO Recommendations for the application. Ann Oncol.2007;18(Suppl 2):ii89-ii91.
72. Weiss AJ, Lackman RD. Infusional chemotherapy combined with recombinant human granulocyte colony stimulating factor: advantages and limitations. Am J Clin Oncol. 1997;20:63-68.
73. Lokich J. Same-day pegfilgrastim and chemotherapy. Cancer Invest. 2005;23:573-576.
74. Lokich JJ. Same day Pegfilgrastim and CHOP chemotherapy for non-Hodgkin lymphoma. Am J Clin Oncol. 2006;29:361-363.
75. van Der Auwera P, Platzer E, Xu ZX, et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol. 2001;66:245-251.
76. Gilmore GL, DePasquale DK, Fischer BC, Shadduck RK. Enhancement of monocytopoiesis by granulocyte colony-stimulating factor: evidence for secondary cytokine effects in vivo. Exp Hematol. 1995; 23:1319-1323.
77. Zhan Y, Lieschke GJ, Grail D, Dunn AR, Cheers C. Essential roles for granulocyte-macrophage colony-stimulating factor (GM-CSF) and G-CSF in the sustained hematopoietic response of Listeria monocytogenesinfected mice. Blood. 1998;91:863-869.
78. Nishihara M, Wada Y, Ogami K, et al. A combination of stem cell factor and granulocyte colony-stimulating factor enhances the growth of human progenitor B cells supported by murine stromal cell line MS-5. Eur J Immunol. 1998;28:855-864.
79. Yamada T, Kaneko H, Iizuka K, Matsubayashi Y, Kokai Y, Fujimoto J. Elevation of lymphocyte and hematopoietic stem cell numbers in mice transgenic for human granulocyte CSF. Lab Invest. 1996;74:384-394.
80. Vanstraelen G, Frere P, Ngirabacu MC, Willems E, Fillet G, Beguin Y. Pegfilgrastim compared with filgrastim after autologous hematopoietic peripheral blood stem cell transplantation. Exp Hematol. 2006;34:382-388.